Growth Metrics

AC Immune (ACIU) Accumulated Depreciation & Amortization (2016)

AC Immune (ACIU) reported Accumulated Depreciation & Amortization of $2.2 million for Q4 2016.

AC Immune (ACIU) has 1 years of Accumulated Depreciation & Amortization data on file, last reported at $2.2 million in Q4 2016.

  • Quarterly Accumulated Depreciation & Amortization changed N/A year-over-year to $2.2 million in Q4 2016, while the trailing twelve-month figure through Dec 2016 was $2.2 million (changed N/A YoY) and the FY2016 annual result came in at $2.2 million, changed N/A from the prior year.
  • Accumulated Depreciation & Amortization was little changed at $2.2 million in Q4 2016 per ACIU's latest filing.
  • Across five years, Accumulated Depreciation & Amortization topped out at $2.2 million in Q4 2016 and bottomed at $2.2 million in Q4 2016.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn
7 Evaxion A 62.56 Bn 62.54 Bn -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn
10 AC Immune 325.88 Mn 211.53 Mn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2016 2.16 Mn
Dec 31, 2016 2.16 Mn